Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/8/2025

Prognostic Factors in Invasive Breast Carcinoma

Core Pathological Prognostic Factors

  • The number of involved axillary lymph nodes is the single most powerful traditional prognostic factor, with the extent of nodal involvement significantly impacting recurrence and survival risk 1, 4
  • Tumor size directly correlates with recurrence risk and mortality, with tumors ≤0.5 cm having a favorable prognosis that adjuvant systemic therapy provides minimal incremental benefit 2, 3, 5
  • Tumor grade using standardized grading systems is consistently identified as one of the strongest prognostic factors and is the only significant factor for metastasis-free survival in multivariate analyses 1, 4

Biomarker-Based Prognostic Factors

  • ER and PgR expression are both prognostic and predictive factors, with high ER expression associated with better prognosis but lesser absolute benefit from chemotherapy 1, 4
  • HER2 status is both prognostic and predictive, determining eligibility for anti-HER2 therapies 1, 2, 3

Integrated Clinical Prognostic Tools

  • The ESMO guidelines recommend using integrated clinical-pathological scoring systems that combine multiple prognostic factors, such as the Nottingham Prognostic Index (NPI) and PREDICT score 1, 4
  • The NPI combines tumor size, grade, and nodal status, while the PREDICT score incorporates age, tumor stage, ER expression, and histological grade 1, 4
  • Patient age is consistently identified as a strong prognostic factor, with younger age generally associated with more aggressive disease biology 2, 3, 5
  • Comorbidity status impacts overall survival and treatment tolerance, influencing treatment decisions 2, 3, 5

Post-Treatment Prognostic Factors

  • After neoadjuvant systemic treatment, the response to treatment and amount of residual disease are critical prognostic factors 1, 4
  • Standardized evaluation of post-neoadjuvant surgical specimens is essential, with pathological complete response associated with improved outcomes 1

REFERENCES